sFas Receptor, human recombinant protein
soluble Fas receptor (sFasR), TNFRSF6, CD95, Apo I, Fas Antigen
|Calculated MW||17.6 kDa|
|Other Names||soluble Fas receptor (sFasR), TNFRSF6, CD95, Apo I, Fas Antigen|
|Sequence||MRLSSKSVNA QVTDINSKGL ELRKTVTTVE TQNLEGLHHD GQFCHKPCPP GERKARDCTV NGDEPDCVPC QEGKEYTDKA HFSSKCRRCR LCDEGHGLEV EINCTRTQNT KCRCKPNFFC NSTVCEHCDP CTKCEHGIIK ECTLTSNTKC KEEGSRS|
|Application Notes||Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.|
|Storage||-20°C; Sterile filtered through a 0.2 micron filter. Lyophilized with no additives.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Fas and Fas Ligand (FasL) belong to the TNF superfamily and are type I and type II transmembrane proteins, respectively. Binding of FasL to Fas triggers apoptosis in Fas-bearing cells. The mechanism of apoptosis involves recruitment of pro-caspase 8 through an adaptor molecule called FADD followed by processing of the pro-enzyme to active forms. These active caspases then cleave various cellular substrates leading to the eventual cell death. sFasR is capable of inhibiting FasL induced apoptosis by acting as a decoy receptor that serves as a sink for FasL. The full length Fas (receptor) is a 319 amino acid type I transmembrane protein, which contains a 157 amino acid extracellular domain, a 17 amino acid transmembrane domain, and 145 amino acid cytoplasmic domain. Recombinant human soluble Fas (sFas Receptor) is a 157 amino acid polypeptide (17.6 kDa) corresponding to the TNFR homologous cysteine rich extracellular domain Fas.
Itoh N.,et al.Cell 66:233-243(1991).
Oehm A.,et al.J. Biol. Chem. 267:10709-10715(1992).
Liu C.,et al.Biochem. J. 310:957-963(1995).
Cascino I.,et al.J. Immunol. 154:2706-2713(1995).
Cascino I.,et al.J. Immunol. 156:13-17(1996).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.